Sulindac Sulfide, but Not Sulindac Sulfone, Inhibits Colorectal Cancer Growth

Neoplasia

Volumn 1, Issue 2, 1999, Pages 170-176

  Williams, Christopher S ^a   Goldman, Angela P ^a   Sheng, Hongmiao ^a   Morrow, Jason D ^b   DuBois, Raymond N ^a,c,d  

^a Department of Medicine ^*  (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemoprevention; Colorectal cancer; Sulindac; Sulindac sulfide; Sulindac sulfone

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DRUG DERIVATIVE; ISOENZYME; LAMININ; MATRIGEL; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEOGLYCAN; PTGS1 PROTEIN, MOUSE; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; COLORECTAL TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GAS CHROMATOGRAPHY; METABOLISM; MOUSE; NUDE MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; TIME; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIVISION; CHROMATOGRAPHY, GAS; COLLAGEN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ISOENZYMES; LAMININ; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEOGLYCANS; SULINDAC; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033139531     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900024     Document Type: Article

References (25)

1. Thun MJ, Namboodiri MM, and Heath CWJ (1991). Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325, 1593-1596.
2. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, and Willett WC (1994). Aspirin use and the risk for colorectal cancer and adenoma in mala health professionals. Ann Intern Med 121, 241-246.
3. [31 Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, and Offerhaus GJ (1993). Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328, 1313-1316.
4. Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JH, Bilinski RT, Martucci C, Newmark HL, Chadbum A, and Bertagnolli MM (1998). The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 19, 87-91.
5. Samaha HS, Kelloff GJ, Steele V, Rao CV, and Reddy BS (1997). Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 57, 1301-1305.
6. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, and Kinzler KW (1996). Sulindac suppresses tumorigenesis in the min mouse. Carcinogenesis 17, 1757-1760.
7. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, and Ahnen DJ (1997). Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57, 2452-2459.
8. Piazza GA, Alberts DS, Hixson U, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperf G, Ritchie, J, Burt RW, Ellsworth L, Ahnen DJ, and Pamukcu R (1997). Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57, 2909-2915.
9. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, DuBois RN, Jetton T, and Morrow J (1997). EGF receptor activation induces nuclear targeting of COX-2, basolateral release of prostaglandins and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 94, 657-662.
10. DuBois RN, Awad J, Morrow J, Roberts LJ, and Bishop PR (1994). Regulation of eicosanoid production and mitogenesis In rat intestinal epithelial cells by transforming growth factor-a and phorbol ester. J Clin Invest 93, 493-498.
11. DuBois RN, Shao J, Sheng H, Tsujii M, and Beauchamp RD (1996). G1 delay in intestinal epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 56, 733-737.
12. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey R, Morrow J, Beauchamp RD, and DuBois RN (1997). Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99, 2254-2259.
13. Wang JL, Sun L, Myeroff X, Wang LE, Gentry J, Yang J, Liang E, Zborowska S, Markowitz JK, Willson, and Brattain MG (1995). Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270, 22044-22049.
14. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, Morrow JD, and DuBois RN (1998). Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis.
15. Rigas B, Goldman IS, and Levine L (1993). Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122, 518-523.
16. Waddell WR, and Loughry RW (1983). Sulindac for polyposis of the colon. J Surg Oncol 24, 83-87.
17. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, and Offerhaus GJ (1993). Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328, 1313-1316.
18. Hanif R, Pittas A, Feng Y, Koutsos Ml, Qiao L, Staiano-Coico L, Shiff SI, and Rigas B (1996). Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52, 237-245.
19. Ravis WR, Diskin CJ, Campagna KD, Clark CR, and McMillian CL (1993). Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. J Clin Pharmacol 33, 527-534.
20. Strong HA, Warner NJ, Renwick AG, and George CF (1985). Sulindac metabolism: the importance of an intact colon. Clin Pharmacol Ther 38, 387-393.
21. Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R, et al. (1995). Antineoplastic drugs sulindac sulfide and sulfone inhibit 'cell growth by Inducing apoptosis. Cancer Res 55, 3110-3116.
22. Thompson HJ, Jiang C, Lu JX, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, and Ahnen DJ (1997). Sulfone metabolite of sulindac inhibits mammary Carcinogenesis. Cancer Res 57, 267-271.
23. Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, and Ahnen DJ (1997). Sulfone metabolite of sulindac inhibits mammary Carcinogenesis. Cancer Res 57, 267-271.
24. Reddy BS, Wang CX, and Maruyama H (1987). Effect of restricted caloric intake on azoxymethane-induced colon tumor incidence in male F344 rats. Cancer Res 47, 1226-1228.
25. Kumar SP, Roy SJ, Tokumo K, and Reddy BS (1990). Effect of different levels of calorie restriction on azoxymethane-induced colon carcinogenesis in male F344 rats. Cancer Res 50, 5761-5766.